Gritstone Oncology is a privately-held, next-generation personalized cancer immunotherapy company. Gritstone brings together distinguished scientific founders, an experienced and diverse management team, a seasoned and successful board of directors, and deep financial backing to tackle fundamental challenges at the intersection of cancer genomics, immunology, and immunotherapy design. The companyÍs initial goal is to identify and deploy therapeutic neoantigens from individual patientsÍ tumor to develop novel treatments for lung cancer.